Influenza a virus vaccines containing purified recombinant h3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

Journal of Infectious Diseases

Volumn 171, Issue 6, 1995, Pages 1595-1599

  Powers, Douglas C ^a,b,c   Smith, Gale E ^a,b,c   Anderson, Edwin L ^a,b,c   Kennedy, Donald J ^a,b,c   Hackett, Craig S ^a,b,c   Wilkinson, Bethanie E ^a,b,c   Volvovitz, Franklin ^a,b,c   Belshe, Robert B ^a,b,c   Treanor, John J ^a,b,c  

^a SAINT LOUIS UNIVERSITY   (United States)

^b MicroGeneSys Inc   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; PLACEBO; RECOMBINANT UNCLEAVED HEMAGGLUTININ; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERANCE; ERYTHEMA; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCLE STIFFNESS; MYALGIA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOUBLE-BLIND METHOD; HEMAGGLUTININS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; VACCINES, SYNTHETIC;

EID: 0029052912     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/171.6.1595     Document Type: Article

References (15)

1. Immunization Practices Advisory Committee. Prevention and control ofinfluenza: part I, vaccines. Morb Mortal Wkly Rep 1993;42:1-14.
2. Ada GL, Jones PD. The immune response to influenza infection. Curr Top Microbiol Immunol 1986;128:1-54.
3. Nichol KL, Lofgren RP, Gapinski J. Influenza vaccination: knowledge, attitudes, and behavior among high-risk outpatients. Arch Intern Med 1992;152:106-10.
4. Robertson JS, Bootman JS, Newman R, et al. Structural changes in the haemagglulinins which accompany egg adaptation of an influenza A (H1N1) virus. Virology 1987; 160:31-7.
5. Katz JM, Naeve CW, Webster RG. Host cell-mediated variation in H3N2 influenza viruses. Virology 1987;156:386-95.
6. Katz JM, Webster RG. Efficacy of inactivated influenza virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J Infect Dis 1989;160:191-8.
7. Murphy BR, Phelan MA, Nelson DL, et al. Hemagglutinin-specific „ enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol 1981;13:554-60.
8. Treanor JJ, Betts RF. Evaluation oflive attenuated cold-adapted influenza B/Yamagata/16/88 reassortant virus vaccine in healthy adults. J Infect Dis 1993;168:455-9.
9. Quinnan GV, Schooley R, Dolin R, Ennis FA, Gross P, Gwaltney JM. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev Infect Dis 1983;5:748-57.
10. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebocontrolled trial. JAMA 1990;264:1139-41.
11. Luckow VA, Summers MD. Trends in the development of baculovirus expression vectors. Biotechnology 1988;6:47-55.
12. Skehel JJ, Stevens DJ, Daniels RS, et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sei USA 1984;81:1779-83.
13. Gallagher P, Henneberry J, Wilson IA, Sambrook J, Gething MJ. Addition of carbohydrate side chains at novel sites on influenza virus hemagglutinin can modulate the folding, transport, and activity of the molecule. J Cell Biol 1988;107:2059-73.
14. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972;268:1329-32.
15. Kendal AP, Noble GR, Dowdle W. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J Infect Dis 1977; 136:S415-24.